{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:47:40Z","timestamp":1788536860285,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"DOI":"10.1186\/s12871-025-03052-8","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:09:42Z","timestamp":1744358982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Determination of ED90 and ED99 of Oliceridine combined with Propofol in inhibiting responses to gastroscope insertion: a biased coin up-and-down design"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhiyong","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghang","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"3052_CR1","doi-asserted-by":"publisher","unstructured":"Simons P, van der Schrier R, van Lemmen M, et al. Respiratory effects of biased ligand Oliceridine in older volunteers: A Pharmacokinetic-Pharmacodynamic comparison with morphine. Anesthesiology. 2023;138(ANESTHESIOLOGY). https:\/\/doi.org\/10.1097\/ALN.0000000000004473.","DOI":"10.1097\/ALN.0000000000004473"},{"issue":"6","key":"3052_CR2","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/ALN.0000000000004758","volume":"139","author":"L Moss","year":"2023","unstructured":"Moss L, Hijma H, Demitrack M, et al. Neurocognitive effect of biased \u00b5-Opioid receptor agonist Oliceridine, a utility function analysis and comparison with morphine. Anesthesiology. 2023;139(6):746\u201356. https:\/\/doi.org\/10.1097\/ALN.0000000000004758.","journal-title":"Anesthesiology"},{"key":"3052_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00232-x","author":"M Brzezinski","year":"2021","unstructured":"Brzezinski M, Hammer GB, Candiotti KA, et al. Low incidence of Opioid-Induced respiratory depression observed with Oliceridine regardless of age or body mass index: exploratory analysis from a phase 3 Open-Label trial in postsurgical pain. PAIN THER. 2021. https:\/\/doi.org\/10.1007\/s40122-020-00232-x. 10 PAIN THER.","journal-title":"PAIN THER"},{"issue":"5","key":"3052_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/cpdd.750","volume":"9","author":"AN Nafziger","year":"2020","unstructured":"Nafziger AN, Arscott KA, Cochrane K, Skobieranda F, Burt DA, Fossler MJ. The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of Oliceridine. Clin Pharmacol Drug Dev. 2020;9(5):639\u201350. https:\/\/doi.org\/10.1002\/cpdd.750. Epub 2019 Nov 7. PMID: 31697049; PMCID: PMC7383509.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3052_CR5","doi-asserted-by":"publisher","unstructured":"Niu J, Hu W, Lu Y et al. Efficacy and safety of oliceridine treatment in patients with postoperative pain: a systematic review and meta-analysis of randomized controlled trials. EXPERT REV CLIN PHAR. 2023; 16 EXPERT REV CLIN PHAR. https:\/\/doi.org\/10.1080\/17512433.2023.2213889","DOI":"10.1080\/17512433.2023.2213889"},{"key":"3052_CR6","doi-asserted-by":"publisher","unstructured":"Kaye AD, Edinoff AN, Babin KC et al. Pharmacological Advances in Opioid Therapy: A Review of the Role of Oliceridine in Pain Management. PAIN THER. 2021; 10 PAIN THER. https:\/\/doi.org\/10.1007\/s40122-021-00313-5","DOI":"10.1007\/s40122-021-00313-5"},{"key":"3052_CR7","doi-asserted-by":"publisher","unstructured":"Hammer GB, Khanna AK, Michalsky C et al. Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials. PAIN THER. 2021; 10 PAIN THER. https:\/\/doi.org\/10.1007\/s40122-021-00299-0","DOI":"10.1007\/s40122-021-00299-0"},{"key":"3052_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/JPR.S171013","volume":"12","author":"ER Viscusi","year":"2019","unstructured":"Viscusi ER, Skobieranda F, Soergel DG, et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating Oliceridine (TRV130), a G protein-biased ligand at the \u00b5-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927\u201343. https:\/\/doi.org\/10.2147\/JPR.S171013.","journal-title":"J Pain Res"},{"key":"3052_CR9","doi-asserted-by":"publisher","unstructured":"Bergese S, Berkowitz R, Rider P et al. Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis. PAIN RES MANAG. 2020; 2020 PAIN RES MANAG. https:\/\/doi.org\/10.1155\/2020\/7492865","DOI":"10.1155\/2020\/7492865"},{"issue":"10","key":"3052_CR10","doi-asserted-by":"publisher","first-page":"e19076","DOI":"10.7759\/cureus.19076","volume":"13","author":"A Shah","year":"2021","unstructured":"Shah A, Shah R, Fahim G, et al. A dive into Oliceridine and its novel mechanism of action. Cureus. 2021;13(10):e19076. https:\/\/doi.org\/10.7759\/cureus.19076.","journal-title":"Cureus"},{"issue":"5","key":"3052_CR11","doi-asserted-by":"publisher","first-page":"e230041","DOI":"10.57264\/cer-2023-0041","volume":"13","author":"J Biskupiak","year":"2023","unstructured":"Biskupiak J, Oderda G, Brixner D, et al. Gastrointestinal adverse effects associated with the use of intravenous Oliceridine compared with intravenous hydromorphone or Fentanyl in acute pain management utilizing adjusted indirect treatment comparison methods. J COMP EFFECT RES. 2023;13(5):e230041. https:\/\/doi.org\/10.57264\/cer-2023-0041.","journal-title":"J COMP EFFECT RES"},{"issue":"1","key":"3052_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40122-020-00216-x","volume":"10","author":"TL Beard","year":"2020","unstructured":"Beard TL, Michalsky C, Candiotti KA, et al. Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: exploratory analysis from two phase 3 randomized placebo and active controlled trials. PAIN THER. 2020;10(1):401\u201313. https:\/\/doi.org\/10.1007\/s40122-020-00216-x.","journal-title":"PAIN THER"},{"issue":"1","key":"3052_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.0006-341x.2002.00171.x","volume":"58","author":"M Stylianou","year":"2002","unstructured":"Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics. 2002;58(1):171\u20137. https:\/\/doi.org\/10.1111\/j.0006-341x.2002.00171.x.","journal-title":"Biometrics"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-025-03052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-025-03052-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-025-03052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:09:43Z","timestamp":1744358983000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-025-03052-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3052"],"URL":"https:\/\/doi.org\/10.1186\/s12871-025-03052-8","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki. This study was approved by the Ethics Committee of the First Affiliated Hospital of Dali University on October 8, 2024. Written informed consent was obtained from all participants. The study was registered in the Chinese Clinical Trial Registry (ChiCTR2400092318) on November 14, 2024. Patient recruitment occurred between November 20 and November 30, 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}